1. Background {#sec93721}
=============

Type 2 diabetes mellitus (T2DM) is a multifactorial and heterogeneous dysglycemic condition due to insulin deficiency of the pancreatic β cells or insulin resistance of the glucose consumer cells ([@A21696R1]). Gestational diabetes mellitus (GDM) is an impaired glucose tolerance (IGT) first diagnosed in pregnancy that can convert to T2DM as a major world health concern ([@A21696R2]).

The GDM prevalence in the United States is about 14%, which has been increased during last years due to obesity, fatty diets, and sedentary lifestyle ([@A21696R3]-[@A21696R5]). In Iran, approximately 4.8% of pregnancies become complicated with GDM ([@A21696R6]). This incidence is not the same in different regions of the country; for example, this is higher in southern parts of Iran (8.9%) ([@A21696R7]).

The placental released factors during pregnancy such as human chorionic somatomammotropin (hCS), tumor necrosis factor α, interleukin 6, and leptin that induce insulin resistance and could lead to GDM ([@A21696R3]).

Following delivery of placenta as a source of anti-insulin hormones, GDM would be mostly resolved. However, these patients will be at a higher risk for T2DM and metabolic syndrome (MetS) in the coming years ([@A21696R2], [@A21696R8], [@A21696R9]).

Generally, T2DM rate in women with previous GDM is about 3% to 65% ([@A21696R10]). Women with a history of GDM are at seven-fold higher risk for developing T2DM in next years ([@A21696R11]).

Considering the different follow-up time and many other factors, the risk of progressing to T2DM is different. In North America, T2DM incidence in women with previous GDM was 2% to 38% during one year of delivery, which is partially depended on ethnicity and severity of glucose intolerance during pregnancy ([@A21696R12], [@A21696R13]). These patients are being recognized to show a great tendency toward developing T2DM in following five years as well as in next ten years with a slower slope ([@A21696R4]). In other studies, 33% to 50% of women with a history of GDM developed T2DM in following five years and 35% to 60% of them in the next ten years ([@A21696R14]).

Other risk factors in mothers with a history of GDM are caesarian delivery and preeclampsia. Their children's complications include congenital anomalies, macrosomia, and neonatal hypoglycemia ([@A21696R15]).

There are several maternal risk factors for developing T2DM. Some of the known predicting factors include older maternal age ([@A21696R10]), pre-pregnancy overweightness ([@A21696R16]), after delivery high body mass index (BMI) ([@A21696R17]-[@A21696R19]) needed dose of insulin ([@A21696R20]), severity of glucose imbalance during pregnancy ([@A21696R21]), history of delivering macrosomic neonate ([@A21696R22]), parity \> 2 ([@A21696R20], [@A21696R23]), anti-β cells anti-bodies in pancreas ([@A21696R24]), GDM diagnosis at early pregnancy ([@A21696R25]), elevated fasting blood sugar (FBS) or blood sugar in 75 g oral glucose tolerance test (OGTT) ([@A21696R18]), low socio-economic status, and urban residence ([@A21696R10]). In addition, weight gain between two pregnancies increases the risk of T2DM development ([@A21696R26], [@A21696R27]).

The worldwide increasing incidence of DM and MetS causes huge financial burden to the society. Identifying GDM as a "trigger" of T2DM and subsequently MetS in these patients and their offspring shows that their sugar must be controlled tightly ([@A21696R9]).

Considering these complications of GDM, there are a small number of studies in developing countries that follow this target longer than a few weeks. The present study goal was to determine T2DM incidence and the related risk factors and MetS frequency after one to two years of delivery as a longer interval in the foresaid population.

2. Objectives {#sec93722}
=============

We conducted this study to determine the incidence and risk factors of developing T2DM, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), and MetS among women with previous GDM in one to six years after delivery.

3. Patients and Methods {#sec93727}
=======================

3.1. Patients {#sec93723}
-------------

In the present study, we extracted the demographic characteristics of women with a history of GDM who were visited and followed in the Endocrinology Clinic of a teaching hospital in Zanjan Province, Iran. All women with a history of GDM who had delivered during 2004 - 2010 in three main hospitals in Zanjan were called to perform laboratory tests and to collect the clinical information. A total of 165 women were called and finally, 110 women with a history of GDM accepted to participate in the study.

3.2. Measurements {#sec93724}
-----------------

Anthropometric characteristics including height (using stadiometer), and weight (using Seca scale with the least clothing) were measured. Thereafter, BMI was calculated for all the cases. Waist circumference (WC) was measured at the middle of the subcostal area and the iliac crest with a plastic measure tape. The sedentary blood pressure (BP) was measured by analog sphygmomanometer after five minutes rest.

3.3. Laboratory Data {#sec93725}
--------------------

After at least 12 to 14 hours of fasting, the participants were referred to the predetermined laboratory to draw the blood sample and test for the FBS, OGTT, lipids, and glycosylated hemoglobin (HbA~1~C). Obviously, the known cases of T2DM were not tested for glucose tolerance.

The FBS levels ≥ 126 mg/dL (≥ 6.99 mmol/L) or BS ≥ 200 mg/dL (≥ 11.10 mmol/L) after two hours OGTT established the diagnosis of diabetes. FBS between 100 to 126 mg/dL (5.5-6.99 mmol/L) was defined as IFG and the blood sugar level of 140 to 199 mg/dL (7.77-11.04 mmol/L) in OGTT was defined as IGT. According to the Iranian National Committee of Obesity criteria, MetS was defined as having any three of the following traits: WC \> 95 cm in females; triglyceride (TG) ≥ 150 mg/dL (\> 1.70 mmol/L) or drug consumption for elevated TG levels; high-density lipoprotein (HDL) \< 50 mg/dL (\< 1.30 mmol/L); systolic BP ≥ 130 and/or diastolic BP ≥ 85 mm Hg or receiving antihypertensive drugs; and FBS ≥ 100 mg/dL (≥ 5.55 mmol/L) or consuming antiglycemic agents ([@A21696R28]).

3.4. Statistical Analysis {#sec93726}
-------------------------

Values were expressed as mean ± standard deviation (SD), and number (percentage), as appropriate. Comparisons were performed by independent-samples t-test for continuous variables and Chi square test for categorical variables. Logistic regression models were used to evaluate the association between GDM and study variables and the dependent variable was a combined variable of IFG, IGT, and DM.

Analysis of the data was performed by SPSS 16.0 (SPSS Inc, Chicago, Illinois, the United States). This study was approved by the ethic committee of Zanjan University of Medical Sciences. The written informed consent was obtained from all of the participants.

4. Results {#sec93728}
==========

In this study, 110 women with a history of GDM with a mean period of 22.8 ± 1.92 months since delivery were included. Thirty-six women (32.7%) had developed T2DM; 11 (10%) IFG (one woman) or IGT (10 women). Moreover, 22 women (20%) had developed with MetS.

Women without normal results in glucose tolerance test (Non-NGT) had a mean BMI of that was higher than that of NGT group; however, the difference was not statistically significant (P = 0.09) ([Table 1](#tbl24012){ref-type="table"}). In non-NGT group, 72% of women were \> 34 years old which was not statistically significant (P = 0.17) in comparison with NGT group (60%). Women in the Non-NGT group required a larger amount of insulin during pregnancy than the NGT group did but the difference was not statistically significant different (34 ± 24.3 vs 25 ± 14.4 units/day; P = 0.06). The Non-NGT group had a significantly longer interval between delivery and laboratory tests (OR, 1.02; P = 0.02). In Non-NGT group, 93.6% had FBS ≥ 95 mg/dL (≥ 5.27 mmol/L) at the time of performing OGTT that was significantly higher than that of the NGT group (42.9%) (OR, 19.55; P \< 0.0001). No insulin use during pregnancy was demonstrated as a protective factor in women with a history of GDM (OR, 0.35; P = 0.01).

There was no significant difference in maternal weight, WC, family history of DM, and history of macrosomic or large for gestational age neonate between two groups. The Non-NGT participants were significantly different with NGT in the number of parities (2.61 ± 1.4 and 2.05 ± 1.1, respectively; OR, 1.41; P = 0.03). According to [Table 2](#tbl24013){ref-type="table"} only the FBS ≥ 95 (≥ 5.27 mmol/L) at the time of OGTT in the index pregnancy had a significant association with developing abnormal glycemic test in the multivariate analysis (OR, 20.55; P \< 0.0001). As shown in [Figure 1](#fig18041){ref-type="fig"} 53% of the patients had FBS ≥ 100 mg/dL (≥ 5.55 mmol/L) as the most frequent component of MetS.

###### Characteristics of Normal and Abnormal Glycemic Test Groups ^[a](#fn22137){ref-type="table-fn"}^

  Variables                                          NGT ^[b](#fn22138){ref-type="table-fn"}^   Non NGT ^[b](#fn22138){ref-type="table-fn"}^   OR (95% CI)         P Value
  -------------------------------------------------- ------------------------------------------ ---------------------------------------------- ------------------- -----------
  **Maternal weight, kg**                            71 ± 11.5                                  74 ± 11.3                                      1.02 (0.98-1.05)    0.23
  **BMI, kg/m** ^**2**^                              28 ± 4.0                                   29 ± 4.1                                       1.09 (0.98-1.21)    0.09
  **Waist circumference, cm**                        92 ± 11.9                                  95 ± 8.8                                       1.02 (0.98-1.06)    0.18
  **Neonatal birth weight, g**                       3362 ± 624                                 3242 ± 663                                     1.00 (0.99-1.00)    0.36
  **Parity, No.**                                    2.05 ± 1.1                                 2.61 ± 1.4                                     1.41 (1.03-1.94)    0.03
  **Delivery and follow-up lab test interval, mo**   18.5 ± 17.7                                27 ± 18.8                                      1.02 (1.00-1.04)    0.02
  **Age \> 34 y**                                                                                                                                                  0.17
  Yes                                                37 (59.7)                                  34 (72.3)                                      1.76 (0.78-3.99)    
  No                                                 25 (40.3)                                  13 (27.7)                                      1.00                
  **Family history of diabetes mellitus**                                                                                                                          0.62
  Yes                                                23 (36.5)                                  15 (31.9)                                      1.00                
  No                                                 40 (63.5)                                  32 (68.1)                                      0.82 (0.37-1.81)    
  **FBS ≥ 95 mg/dL (≥ 5.27 mmol/L)**                                                                                                                               \< 0.0001
  Yes                                                27 (42.9)                                  44 (93.6)                                      19.55 (5.4-69.74)   
  No                                                 36 (57.1)                                  3 (6.4)                                        1.00                
  **History of delivering macrosomic neonate**                                                                                                                     0.42
  Yes                                                3 (4.8)                                    4 (8.7)                                        1.00                
  No                                                 59 (95.2)                                  42 (91.3)                                      0.53 (0.11-2.51)    
  **Insulin use**                                                                                                                                                  0.01
  Yes                                                37 (58.7)                                  37 (80.4)                                      1.00                
  No                                                 26 (41.3)                                  9 (19.6)                                       0.35 (0.14-0.83)    

^a^ Abbreviations: BMI, body mass index; FBS, fasting blood glucose; and NGT, normal glycemic test.

^b^ Data are presented as mean ± SD or No. (%).

###### The Multivariate Analysis of Target Risk Factors

  Variable                                               OR (95% CI)          P Value
  ------------------------------------------------------ -------------------- -----------
  **Parity**                                             1.40 (0.97-2.17)     0.33
  **Delivery and follow-up lab test interval, months**   1.02 (0.99-1.05)     0.10
  **FBS ≥ 95 mg/dL (≥ 5.27 mmol/L)**                     20.55 (5.19-81.31)   \< 0.0001

![Frequency of Metabolic Syndrome Components in the Patients With Previous Gestational Diabetes Mellitus](ijem-13-02-21696-i001){#fig18041}

5. Discussion {#sec93729}
=============

Of the 110 studied women with a history of GDM, one-third had developed T2DM and one-fifth MetS according to the Iranian National Committee of Obesity on average 23 months postpartum, which were higher than that expected rates. In the univariate analysis, the risk factors for developing T2DM included FBS ≥ 95 mg/dL (≥ 5.27 mmol/L) at the time of GDM diagnosis, interval between delivery and follow-up lab test, and need to insulin therapy during pregnancy; however, in the multivariate analysis, FBS ≥ 95 mg/L (≥ 5.27 mmol/L) was expressed to be the only risk factor.

Russell et al. study in Canada reported the cumulative incidence of T2DM at one, five, and ten years of previous delivery to be 5.9%, 14.8%, and 22.2%, respectively. In this retrospective cohort study the risk factors for developing T2DM included a pre-pregnancy weight \> 86 kg (RR = 1.8; 95% CI, 1.2-2.9), need to insulin therapy during pregnancy (RR = 4.1; 95% CI, 2.1-7.9), a pregnancy following the GDM (RR = 2.3; 95% CI, 1.6-3.4), and neonatal hypoglycemia (RR = 2.6; 95% CI, 1.6-4.2). The T2DM incidence after ten years in Russell et al. study was less than that in our study with a shorter follow-up period. Our investigation showed a higher incidence of T2DM in women with history of previous GDM ([@A21696R29]). This remarkable difference may refer to the demographic variables of the studied groups, which was nulliparous women with a mean age of 28 years old with 4% needing insulin therapy in the Canadian study versus multiparous with the mean age of 32 years old with \> 65% needing insulin therapy (more severe GDM) in our study.

Lauenborg et al. study on a Danish population after median of 9.8 years of the index pregnancy reported diabetes and IFG/IGT incidence to be 40.0% and 27.0%, respectively. They found pre-pregnancy overweightness and postpartum IGT were independently associated with increased risk of DM ([@A21696R30]). The rate of T2DM in their study was lower than the rate in our study due to different follow-up periods. In addition, they presented different predictors for progressing to DM.

In a systematic review by Kim et al. the cumulative incidence of diabetes was reported to range from 2.6% to 70% in the studies with different follow-up periods (6 weeks to 28 years). They deducted steeper slope in incidence of T2DM in the five versus ten years of delivery. The elevated FBS during pregnancy was identified as a risk for future DM ([@A21696R4]), which was similar to our study.

Comparing with the foresaid studies, the T2DM rate in our observed population was relatively high. This result might be related to ethnicity; however, we cannot disregard the influence of referral bias in our study. Our patients were recruited from a tertiary center that women with severe GDM were more likely to be referred to while the mild cases are handled by the obstetricians. Girgis et al. studied the ethnicity role in T2DM following GDM at mean period of 5.5 years after delivery. The South Asian women were at a higher risk to progress to abnormal GTT (69%) than other ethnicities (P \< 0.05) ([@A21696R31]).

An Iranian study by Tehrani et al. followed patients from Tehran Lipid and Glucose Study (TLGS) up to nine years after delivery. This investigation reported a higher rate of T2DM in women with a history of GDM (27.3%) than women in control group (9.5%) (P \< 0.001). However, number of women with a history of GDM was small (29 women) compared with control group (628 women) ([@A21696R32]).

The role of ethnicity was remarked by Kousta et al. study ([@A21696R33]). They studied on three groups of European, Asian-Indian, and African-Caribbean women with a history of GDM. Considering the incidence of DM being respectively 28%, 44%, and 50% in European, Asian-Indian, and African-Caribbean, there is a significant need for DM prevention and control plans in non-European women ([@A21696R18], [@A21696R33]). Breastfeeding for at least three months after delivery remarkably lowers the risk of T2DM among women with a history of GDM ([@A21696R2]).

One-fifth (20%) of the participants in our study had developed MetS during a mean postpartum period of 22.8 ± 1.92 months. Retnakaran et al. studied the rate of MetS three months postpartum among three groups of women with NGT, gestational IGT, and GDM. The International Diabetes Federation defined MetS incidence was remarkably higher in both GDM (20.0%) and GIGT (17.6%) than in NGT women (10.0%) (Overall P = 0.016). Abnormal WC was more frequent component of MetS, which was in accordance with our study ([@A21696R34]). Moreover, in the Kousta et al. study, MetS was seen in 49%, 43%, and 28% of Asian-Indian, African-Caribbean, and European women, respectively ([@A21696R33]).

Parity ≥ 4, FBS ≥ 95 mg/dL (≥ 5.27 mmol/L) at the time of diagnosing GDM, and need to insulin therapy during pregnancy were the most important risk factors for developing DM. Moreover, Oldfield et al. indicated the pregnancy weight, older maternal age at follow up, enhancing the hyperglycemia, and high amount of insulin needed during pregnancy as the risk factors of developing T2DM ([@A21696R35]).

Our study has several limitations. The sample size was relatively small and the referral bias had probably affected the incidence of T2DM. The advantages of this study were longer period of the follow-up (mean 22.8 ± 1.92 months) than previous studies in Iran and identification the MetS rate in the mentioned population. Future population based studies in Iran with longer follow-up period would more comprehensively clarify the predictors of developing T2DM in women with a history of GDM.

Our findings showed that a large number of women with a history of GDM develop T2DM and glucose intolerance in the following years. In addition, a remarkable percentage of these patients will develop cardiovascular diseases risk factors because of MetS. Therefore, women with a history of GDM should be screened after the appropriate period from delivery in order to discover the women with abnormal glucose tolerance and MetS for the primary necessary interventions.
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